Publications by authors named "C McDanal"
Article Synopsis
- The COVE trial examined the effects of the mRNA-1273 vaccine by randomizing participants to receive either the vaccine or a placebo with key immune responses measured on Days 29 and 57.
- Using new analytical approaches, the study found that varying the antibody levels post-vaccination correlated strongly with vaccine efficacy against COVID-19, estimating effectiveness between 84.2% and 97.6% based on antibody levels.
- Findings indicated consistent results across several immune markers, reinforcing their role as reliable correlates of protection against the virus at both time points of analysis.
Article Synopsis
- - The study analyzed how different variants of SARS-CoV-2 affect immunity, focusing on 21 variants and how they interact with immune responses from people previously infected or vaccinated.
- - Researchers used a technique called antigenic cartography to identify significant differences in the spike protein of pre-Omicron variants, noting key positions that show variability related to immunity.
- - They observed that immunity increases notably 4 weeks to over 3 months after the second vaccine dose, and that the initial variant exposure impacts which parts of the spike protein the immune system focuses on, highlighting considerations for future vaccine strategies.
The best assay or marker to define mRNA-1273 vaccine-induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19 vaccine or placebo. We previously assessed IgG binding antibodies to the spike protein (spike IgG) or receptor binding domain (RBD IgG) and pseudovirus neutralizing antibody 50 or 80% inhibitory dilution titer measured on day 29 or day 57, as correlates of risk (CoRs) and CoPs against symptomatic COVID-19 over 4 months after dose.
View Article and Find Full Text PDFDuring the SARS-CoV-2 pandemic, multiple variants escaping pre-existing immunity emerged, causing concerns about continued protection. Here, we use antigenic cartography to analyze patterns of cross-reactivity among a panel of 21 variants and 15 groups of human sera obtained following primary infection with 10 different variants or after mRNA-1273 or mRNA-1273.351 vaccination.
View Article and Find Full Text PDF